Pcn358 Comparing and Validating the Overall Survival Extrapolations for Immuno-Oncology Treatments Applied in Hta's by Noma and TLV

Abstract

pembrolizumab) were reviewed nearly twice as frequently (35.8%) as TKIs (16.7%). All immunotherapies, except durvalumab, were evaluated by all studied countries, with a majority of decisions published as favorable (58.1%). High cost of immunotherapies was commonly cited as the reason for unfavorable decisions, while increased evidence for clinical benefit in patient subpopulations was often requested for mixed and neutral decisions. Conclusions: More than half of all HTA decisions were categorized as favorable. Immunotherapies were among the most commonly evaluated NSCLC treatments. Further emphasis on developing and evaluating robust health economic and clinical data is necessary as the landscape shifts towards precision medicine.

A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities

“…From our perspective, relative differences are more appropriate, as they take into account the differences in survival prognosis between different cancer types, and in the amount of additional long-term follow-up data available as opposed to absolute differences. Another study evaluated the CE assessment reports of ICIs by the Norwegian Medical Agency ( n = 7) and the Dental and Pharmaceutical Benefits Board ( n = 7) (60). Overall, long-term OS under ICI treatment was again underestimated in 79 percent of the assessment reports ( n = 11/14).…”